Article
Oncology
Dionysis Papadatos-Pastos, Wei Yuan, Abhijit Pal, Mateus Crespo, Ana Ferreira, Bora Gurel, Toby Prout, Malaka Ameratunga, Maxime Chenard-Poirier, Andra Curcean, Claudia Bertan, Chloe Baker, Susana Miranda, Nahal Masrour, Wentin Chen, Rita Pereira, Ines Figueiredo, Ricardo Morilla, Ben Jenkins, Anna Zachariou, Ruth Riisnaes, Mona Parmar, Alison Turner, Suzanne Carreira, Christina Yap, Robert Brown, Nina Tunariu, Udai Banerji, Juanita Lopez, Johann de Bono, Anna Minchom
Summary: The combination of guadecitabine and pembrolizumab improves tumor sensitivity to immune checkpoint inhibitors and reverses previous resistance. This study demonstrates the safety and tolerability of the treatment regimen and observes some anticancer activity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medicine, General & Internal
Robert Motzer, Boris Alekseev, Sun-Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Gruenwald, Thomas E. Hutson, Evgeny Kopyltsov, Maria J. Mendez-Vidal, Vadim Kozlov, Anna Alyasova, Sung-Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frederic Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri
Summary: The study demonstrated that the combination of lenvatinib with pembrolizumab led to significantly longer progression-free survival and overall survival than sunitinib, while the combination of lenvatinib with everolimus showed longer progression-free survival but not overall survival compared to sunitinib. Adverse events were more frequent in patients receiving lenvatinib-based treatments.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
V Makker, N. Colombo, A. Casado Herraez, A. D. Santin, E. Colomba, D. S. Miller, K. Fujiwara, S. Pignata, S. Baron-Hay, I Ray-Coquard, R. Shapira-Frommer, K. Ushijima, J. Sakata, K. Yonemori, Y. M. Kim, E. M. Guerra, U. A. Sanli, M. M. McCormack, A. D. Smith, S. Keefe, S. Bird, L. Dutta, R. J. Orlowski, D. Lorusso
Summary: Lenvatinib plus pembrolizumab significantly prolongs progression-free survival and overall survival compared to chemotherapy in advanced endometrial cancer patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Chi-Jung Wu, Pei-Chang Lee, Ya-Wen Hung, Chieh-Ju Lee, Chen-Ta Chi, I-Cheng Lee, Ming-Chih Hou, Yi-Hsiang Huang
Summary: This study evaluated the efficacy and safety of lenvatinib plus pembrolizumab for unresectable hepatocellular carcinoma (uHCC) patients. The results showed a high disease control rate (DCR) and no adverse effect on liver function score in both systemic therapy-naive and -experienced uHCC patients.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Shigehisa Kitano, Yutaka Fujiwara, Toshio Shimizu, Satoru Iwasa, Kan Yonemori, Shunsuke Kondo, Akihiko Shimomura, Takafumi Koyama, Takahiro Ebata, Hiroki Ikezawa, Nozomi Hayata, Yukinori Minoshima, Takuma Miura, Tomoki Kubota, Noboru Yamamoto
Summary: This study investigates the tolerability and safety of lenvatinib plus pembrolizumab in Japanese patients with metastatic solid tumors. The combination therapy showed favorable antitumor activity and no new safety signals were identified. The results support the use of this treatment in Japanese patients.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2022)
Review
Immunology
Dun-Chang Mo, Peng-Hui Luo, Shang-Xiao Huang, Han-Lei Wang, Jian-Feng Huang
Summary: Based on the systematic review, the combination therapy of pembrolizumab plus lenvatinib showed higher objective response rates and significant survival benefits in certain solid cancers compared to monotherapies, with manageable toxicities and no unexpected safety issues observed.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Lu Wang, Zhenping Cao, Mengmeng Zhang, Sisi Lin, Jinyao Liu
Summary: The study reports a method of spatiotemporally controllable distribution of combination therapeutics in solid tumors mediated by bacteria, which can reprogram the immune microenvironment of the tumor to optimize antitumor efficacy. Combining the localized heating effect of melanin and the immune activation effect of inhibitors can significantly inhibit tumor growth and prolong survival.
ADVANCED MATERIALS
(2022)
Review
Oncology
Domenica Lorusso, Romano Danesi, Laura Deborah Locati, Gianluca Masi, Ugo De Giorgi, Angiolo Gadducci, Sandro Pignata, Sabbatini Roberto, Antonella Savarese, Giorgio Valabrega, Claudio Zamagni, Nicoletta Colombo
Summary: The combination of lenvatinib plus pembrolizumab demonstrates clinical benefit in endometrial carcinoma. The adverse events of lenvatinib can be managed through proactive and thorough monitoring, and early detection. Increased awareness among clinicians is important in maintaining the balance of risk and benefit.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Melissa Johnson, Arkadiusz Z. Dudek, Ammar Sukari, Justin Call, Paul R. Kunk, Karl Lewis, Justin F. Gainor, John Sarantopoulos, Patrice Lee, Adele Golden, Allison Harney, S. Michael Rothenberg, Yuanyuan Zhang, Jonathan W. Goldman
Summary: This study evaluated the safety and preliminary efficacy of ARRY-382 plus pembrolizumab in patients with advanced solid tumors. The results showed limited clinical benefit, but the combination therapy was well tolerated.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Christopher A. Walker, Alexandra N. Spirtos, David S. Miller
Summary: Advanced and recurrent endometrial carcinoma is difficult to treat, especially for patients who are microsatellite stable (MSS) or mismatch repair proficient (pMMR). Recent trials have shown that the combination of pembrolizumab and lenvatinib improves ORR, PFS, and OS compared to current therapies.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Article
Oncology
Jianming Xu, Jiuwei Cui, Haiping Jiang, Yan Zeng, Xiuyu Cong
Summary: This study determined the MTD, RP2D, pharmacokinetics, safety, and preliminary efficacy of EVER4010001 plus pembrolizumab in patients with advanced solid tumors. The results showed that 80 mg BID was the MTD and RP2D for EVER4010001 plus pembrolizumab.
Review
Immunology
Wei Zhang, Chu Luo, Zun-Yi Zhang, Bi-Xiang Zhang, Xiao-Ping Chen
Summary: The combination of lenvatinib and pembrolizumab with GP chemotherapy achieved significant tumor reduction and decreased tumor marker levels in a patient with unresectable ICC. The patient underwent successful liver resection and has survived 15 months without recurrence or metastasis.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Public, Environmental & Occupational Health
Mingyang Feng, Yue Chen, Yang Yang, Qiu Li
Summary: This study investigated the cost-effectiveness of lenvatinib plus pembrolizumab (LP) compared with chemotherapy in pretreated patients with advanced endometrial cancer. The results showed that LP was not cost-effective under the current willingness to pay threshold.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Oncology
William A. Zammarrelli III, Weining Ma, Kevin Espino, Sushmita Gordhandas, Effi Yeoshoua, Sarah Ehmann, Qin Zhou, Alexia Iasonos, Nadeem R. Abu-Rustum, Carol Aghajanian, Angela K. Green, Maria M. Rubinstein, Vicky Makker
Summary: Combination lenvatinib plus pembrolizumab treatment for recurrent endometrial cancer resulted in common adverse events, with no significant difference based on lenvatinib starting doses. Further optimization studies may be needed to guide dosing in clinical practice. Clinical trial data remains crucial for establishing standard dosing protocols.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Kaysia Ludford, Won Jin Ho, Jane V. Thomas, Kanwal P. S. Raghav, Mariela Blum Murphy, Nicole D. Fleming, Michael S. Lee, Brandon G. Smaglo, Y. Nancy You, Matthew M. Tillman, Carlos Kamiya-Matsuoka, Selvi Thirumurthi, Craig Messick, Benny Johnson, Eduardo Vilar, Arvind Dasari, Sarah Shin, Alexei Hernandez, Xuan Yuan, Hongqui Yang, Wai Chin Foo, Wei Qiao, Dipen Maru, Scott Kopetz, Michael J. Overman
Summary: Pembrolizumab has shown significant clinical benefits in advanced MSI-H/dMMR solid tumors. This phase II trial evaluated the use of pembrolizumab in neoadjuvant treatment for localized unresectable or high-risk resectable MSI-H/dMMR tumors. The study demonstrated high rates of response and safety, suggesting potential implications for organ-sparing strategies.
JOURNAL OF CLINICAL ONCOLOGY
(2023)